RxDoctor Payments Data

Ramprasad Kandavar, MD

Nephrology · New Orleans, LANPI 1669558920

Payments from drug & device makers

$2,246in general payments, 2019–2025

Across 73 payments — averaging $30.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$733
  • AstraZeneca$266
  • Vifor Pharma, Inc.$156
  • Calliditas Therapeutics US Inc.$153
  • Otsuka America Pharmaceutical, Inc.$143
  • Fresenius USA Marketing, Inc.$134
  • plus $662 from 14 others

What the payments were for

  • Travel & lodging$62028%
  • Food & beverage$1,50767%
  • Education$1195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,246 in reported general payments places this provider in the 50th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$300,530
Medicare patients
480
Services billed
2,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide42$102,855
ProcritEpoetin Alfa35$28,849
AuryxiaFerric Citrate12$21,179
Sevelamer Carbonate55$10,857
LokelmaSodium Zirconium Cyclosilicate13$7,288
Nifedipine ErNifedipine233$4,016
Calcitriol159$2,061
Hydralazine Hcl120$1,451
Midodrine Hcl14$1,089
Losartan Potassium48$325
Lisinopril42$264
Doxazosin Mesylate18$256
Metoprolol Succinate24$249
Furosemide58$239
Amlodipine Besylate47$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$134$102,85542 claims
Akebia Therapeutics IncAuryxia$90$21,17912 claims
AstraZenecaLokelma$266$7,28813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 206 nephrology providers in Louisiana.

Other nephrology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →